EP300 and acute myeloid leukemia: To further evaluate the possible clinical benefit of the combination strategy, we examined the efficacy of cotreating primary AML cells from patients with varying FLT3-ITD allelic ratios with p300/CBP inhibitors and quizartinib (patient information is provided in Table S3).